|
[1]
|
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 2017;49(3):1700214. http://dx.doi.org/10.1183/13993003.00214-2017CrossRef
|
|
[2]
|
Wang C, Xu JY, Yang L, Xu YJ, Zhang XY, Bai CX, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet 2018;391(10131):1706 − 17. http://dx.doi.org/10.1016/S0140-6736(18)30841-9CrossRef
|
|
[3]
|
Expert Group Opinion on Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in China (updated 2017). Int J Respir 2017;37(14):1041 − 57. http://dx.doi.org/10.3760/cma.j.issn.1673-436X.2017.14.001 (In Chinese). CrossRef
|
|
[4]
|
Li Y, Zhang PS, An ZJ, Yue CY, Wang YM, Liu YQ, et al. Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations. Respirology 2022;27(10):844 − 53. http://dx.doi.org/10.1111/resp.14309CrossRef
|
|
[5]
|
WHO. Considerations for pneumococcal vaccination in older adults. Wkly Epidemiol Rec 2021;96(23):217−28. https://apps.who.int/iris/handle/10665/341722.https://apps.who.int/iris/handle/10665/341722 |
|
[6]
|
Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58(RR-8):1−52. https://pubmed.ncbi.nlm.nih.gov/19644442/.https://pubmed.ncbi.nlm.nih.gov/19644442/ |
|
[7]
|
Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59(34):1102−6. https://pubmed.ncbi.nlm.nih.gov/20814406/.https://pubmed.ncbi.nlm.nih.gov/20814406/ |
|
[8]
|
Koul PA, Nowshehr AA, Khan UH, Jan RA, Shah SU. Cost of severe chronic obstructive pulmonary disease exacerbations in a high burden region in North India. Ann Glob Health 2019;85(1):13. http://dx.doi.org/10.5334/aogh.2423CrossRef
|
|
[9]
|
Liang LR, Li CW, Shen Y, Rong HM, Jing H, Tong ZH. Long-term trends in hospitalization and outcomes in adult patients with exacerbation of chronic obstructive pulmonary disease in Beijing, China, from 2008 to 2017. Int J Chron Obstruct Pulmon Dis 2020;15:1155 − 64. http://dx.doi.org/10.2147/COPD.S238006CrossRef
|
|
[10]
|
Li F, Sun Z, Li H, Yang T, Shi Z. Factors associated with hospitalisation costs in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2018;22(4):458 − 63. http://dx.doi.org/10.5588/ijtld.17.0430CrossRef
|
|
[11]
|
Shah CH, Onukwugha E, Zafari Z, Villalonga-Olives E, Park JE, Slejko JF. Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population. Expert Rev Pharmacoecon Outcomes Res 2022;22(4):683 − 90. http://dx.doi.org/10.1080/14737167.2021.1981291CrossRef
|
|
[12]
|
Maleki-Yazdi MR, Kelly SM, Lam SS, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J 2012;19:328460. http://dx.doi.org/10.1155/2012/328460CrossRef
|
|
[13]
|
Germini F, Veronese G, Marcucci M, Coen D, Ardemagni D, Montano N, et al. COPD exacerbations in the emergency department: epidemiology and related costs. A retrospective cohort multicentre study from the Italian Society of Emergency Medicine (SIMEU). Eur J Intern Med 2018;51:74 − 9. http://dx.doi.org/10.1016/j.ejim.2018.01.010CrossRef
|
|
[14]
|
Ozkaya S, Findik S, Atici AG. The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease. ClinicoEcon Outcomes Res 2011;2011:15 − 8. http://dx.doi.org/10.2147/CEOR.S14820CrossRef
|
|
[15]
|
Ngo CQ, Thi Bui T, Vu GV, Chu HT, Phan PT, Ngoc Pham H, et al. Direct hospitalization cost of patients with acute exacerbation of chronic obstructive pulmonary disease in Vietnam. Int J Environ Res Public Health 2019;16(1):88. http://dx.doi.org/10.3390/ijerph16010088CrossRef
|
|
[16]
|
Qiu YP, Zhao K, Li X, Shi LW, Guo WD, Qi XR, et al. Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China. Chin J Prev Med 2016;50(12):1074-8. https://d.wanfangdata.com.cn/periodical/zhyfyx201612013. (In Chinese). https://d.wanfangdata.com.cn/periodical/zhyfyx201612013 |
|
[17]
|
Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J Med Assoc Thai 2003;86(6):497-508. https://pubmed.ncbi.nlm.nih.gov/12924797/.https://pubmed.ncbi.nlm.nih.gov/12924797/ |
|
[18]
|
Chinese National Influenza Center. Chinese influenza weekly report. https://ivdc.chinacdc.cn/cnic/zyzx/lgzb/202002/P020200221783302893844.pdf. [2021-11-23].https://ivdc.chinacdc.cn/cnic/zyzx/lgzb/202002/P020200221783302893844.pdf |